Literature DB >> 16652075

Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer.

Christine G Gourin1, Haydn T Williams, Wesley N Seabolt, Anne V Herdman, Jed W Howington, David J Terris.   

Abstract

OBJECTIVES: Planned neck dissection after chemoradiation (CR) is often advocated in patients with head and neck squamous cell cancer (HNSCC) with advanced nodal disease who demonstrate a clinical complete response to CR because identification of residual occult nodal disease is difficult. We sought to investigate the utility of positron emission tomography-computed tomography (PET-CT) in identifying patients with occult nodal disease after CR. STUDY
DESIGN: Nonrandomized retrospective cohort analysis.
MATERIALS AND METHODS: The medical records of all patients treated with primary CR for advanced HNSCC with N2 or N3 disease from December 2003 to June 2005 were reviewed. Patients with a clinical complete response were eligible for inclusion if PET-CT performed at 8 to 10 weeks after CR showed no evidence of distant disease and they were treated with a planned neck dissection.
RESULTS: Seventeen patients met study criteria. PET-CT was positive for residual nodal disease in 11 (64.7%) patients, with a standardized uptake value (SUV) range of 1.7 to 3.8. Pathologic examination revealed residual viable carcinoma in five (29.4%) patients, with tumor size ranging from 2.0 to 9.5 mm. Carcinoma was present in 2 of 11 (18.2%) patients with positive PET-CT scans and 3 of 6 (50%) patients with negative PET-CT scans. The sensitivity and specificity of PET-CT in predicting occult nodal disease was 40% and 25%, respectively. There was no correlation between PET-CT findings and histologic findings (P = .26) or between SUV and size of viable tumor (P = .67).
CONCLUSIONS: A significant proportion of HNSCC patients with advanced neck disease harbor residual occult metastases after CR. PET-CT is not sufficiently specific or sensitive to reliably predict the need for posttreatment neck dissection.

Entities:  

Mesh:

Year:  2006        PMID: 16652075     DOI: 10.1097/01.MLG.0000215176.98582.A9

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  17 in total

1.  Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer.

Authors:  James D Murphy; Trang H La; Karen Chu; Andrew Quon; Nancy J Fischbein; Peter G Maxim; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

Review 2.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

3.  PET/CT in head and neck cancer.

Authors:  Liselotte Højgaard; Lena Specht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

Review 4.  Treatment of advanced neck metastases.

Authors:  G Spriano; R Pellini; V Manciocco; P Ruscito
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

5.  Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.

Authors:  Anuj Goenka; Luc G T Morris; Shyam S Rao; Suzanne L Wolden; Richard J Wong; Dennis H Kraus; Nisha Ohri; Jeremy Setton; Benjamin H Lok; Nadeem Riaz; Borys R Mychalczak; Heiko Schoder; Ian Ganly; Jatin P Shah; David G Pfister; Michael J Zelefsky; Nancy Y Lee
Journal:  Int J Cancer       Date:  2013-03-29       Impact factor: 7.396

Review 6.  Positron emission tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.

Authors:  Voichita Bar-Ad; Mark Mishra; Nitin Ohri; Charles Intenzo
Journal:  Rev Recent Clin Trials       Date:  2012-02

7.  Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome.

Authors:  Ian Ganly; Jennifer Bocker; Diane L Carlson; Salvatore D'Arpa; Maria Coleman; Nancy Lee; David G Pfister; Jatin P Shah; Snehal G Patel
Journal:  Head Neck       Date:  2010-11-04       Impact factor: 3.147

8.  Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma.

Authors:  Goshi Nishimura; Kenichiro Yabuki; Masaharu Hata; Masanori Komatsu; Takahide Taguchi; Masahiro Takahashi; Osamu Shiono; Daisuke Sano; Yasuhiro Arai; Hideaki Takahashi; Yoshihiro Chiba; Nobuhiko Oridate
Journal:  Int J Clin Oncol       Date:  2015-12-28       Impact factor: 3.402

Review 9.  Efficacy of neck dissection in the management of isolated nodal recurrence after head and neck cancer treatment.

Authors:  Jimmy Yu-wai Chan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

Review 10.  The "HPV Discussion": Effective Use of Data to Deliver Recommendations to Patients Impacted by HPV.

Authors:  Samir S Khariwala; Michael G Moore; Kelly M Malloy; Benoit Gosselin; Richard V Smith
Journal:  Otolaryngol Head Neck Surg       Date:  2015-07-28       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.